These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32202782)

  • 1. GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.
    Kazmierski WM; Baskaran S; Walker JT; Miriyala N; Meesala R; Beesu M; Adjabeng G; Grimes RM; Hamatake R; Leivers MR; Crosby R; Xia B; Remlinger K
    J Med Chem; 2020 Apr; 63(8):4155-4170. PubMed ID: 32202782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Activity of Combined NS5A Inhibitors.
    O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of fluorobenzimidazole HCV NS5A inhibitors.
    Randolph JT; Flentge CA; Donner P; Rockway TW; Patel SV; Nelson L; Hutchinson DK; Mondal R; Mistry N; Reisch T; Dekhtyar T; Krishnan P; Pilot-Matias T; Stolarik DF; Beno DWA; Wagner R; Maring C; Kati WM
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5462-5467. PubMed ID: 27780635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer M; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1954-1957. PubMed ID: 29653894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.
    Yu W; Tong L; Hu B; Zhong B; Hao J; Ji T; Zan S; Coburn CA; Selyutin O; Chen L; Rokosz L; Agrawal S; Liu R; Curry S; McMonagle P; Ingravallo P; Asante-Appiah E; Chen S; Kozlowski JA
    J Med Chem; 2016 Nov; 59(22):10228-10243. PubMed ID: 27792320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256.
    Yang H; Yang C; Wang Y; Rhodes G; Robinson M; Cheng G; Qi X; Mo H; Tian Y; Pakdaman R; Sheng XC; Kim CU; Delaney WE
    Antivir Ther; 2017; 22(5):413-420. PubMed ID: 28106531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor.
    Liu B; Gai K; Qin H; Wang J; Liu X; Cao Y; Lu Q; Lu D; Chen D; Shen H; Song W; Mei J; Wang X; Xu H; Zhang Y
    J Med Chem; 2020 May; 63(10):5312-5323. PubMed ID: 32293179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier.
    Abdallah M; Hamed MM; Frakolaki E; Katsamakas S; Vassilaki N; Bartenschlager R; Zoidis G; Hirsch AKH; Abdel-Halim M; Abadi AH
    Eur J Med Chem; 2022 Feb; 229():114034. PubMed ID: 34959173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry.
    Ahmed M; Pal A; Houghton M; Barakat K
    ACS Infect Dis; 2016 Nov; 2(11):872-881. PubMed ID: 27933783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor.
    Owens CM; Brasher BB; Polemeropoulos A; Rhodin MH; McAllister N; Wong KA; Jones CT; Jiang L; Lin K; Or YS
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6216-26. PubMed ID: 27503644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
    Gao M
    Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
    St Laurent DR; Serrano-Wu MH; Belema M; Ding M; Fang H; Gao M; Goodrich JT; Krause RG; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle DR; Pearce BC; Romine JL; Valera L; Sun JH; Wang YK; Yang F; Yang X; Meanwell NA; Snyder LB
    J Med Chem; 2014 Mar; 57(5):1976-94. PubMed ID: 23573957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of potent nonstructural protein 5A (NS5A) inhibitors with a unique resistance profile-Part 2.
    Wakenhut F; Tran TD; Pickford C; Shaw S; Westby M; Smith-Burchnell C; Watson L; Paradowski M; Milbank J; Stonehouse D; Cheung K; Wybrow R; Daverio F; Crook S; Statham K; Leese D; Stead D; Adam F; Hay D; Roberts LR; Chiva JY; Nichols C; Blakemore DC; Goetz GH; Che Y; Gardner I; Dayal S; Pike A; Webster R; Pryde DC
    ChemMedChem; 2014 Jul; 9(7):1387-96. PubMed ID: 24729518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.
    Belema M; Nguyen VN; Bachand C; Deon DH; Goodrich JT; James CA; Lavoie R; Lopez OD; Martel A; Romine JL; Ruediger EH; Snyder LB; St Laurent DR; Yang F; Zhu J; Wong HS; Langley DR; Adams SP; Cantor GH; Chimalakonda A; Fura A; Johnson BM; Knipe JO; Parker DD; Santone KS; Fridell RA; Lemm JA; O'Boyle DR; Colonno RJ; Gao M; Meanwell NA; Hamann LG
    J Med Chem; 2014 Mar; 57(5):2013-32. PubMed ID: 24521299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.